|
|
|
| Study on Efficacy and Safety of Agomelatine combined with Transcranial Magnetic Therapy in the treatment of Depression and Anxiety in Perimenopausal Syndrome |
| WU Yanchun, SUN Xue, FANG Jie |
| Zhenjiang Mental Health Center, Jiangsu Zhenjiang 212001, China |
|
|
|
|
Abstract Objective: To study the efficacy and safety of agomelatine combined with transcranial magnetic therapy in the treatment of depression and anxiety in perimenopausal syndrome. Methods: 70 cases of perimenopausal syndrome were diagnosed and treated in our hospital. According to the random number table method, the patients were randomly divided into the control group who was given the agomelatine, and the combined group was treated with transcranial magnetic therapy on the basis of the control group, with 35 cases in each group. All the patients were treated for 2 months. The clinical efficacy, the Hamilton Anxiety Scale (HAMA), the Hamilton Depression Scale (HAMD) before and after treatment and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate of the combined group was 91.43%, which was significantly increased in comparison of the control group in 62.86% (P<0.05). The scores of HAMA and HAMD in the two groups were significantly decreased in comparison of those before treatment, and the rate of reduction in the combined group was more significant than that in the control group (P<0.01). There was no statistically significant difference in the incidence rate of adverse reactions between the two groups during treatment (P>0.05). Conclusion: The combined treatment of agomelatine and transcranial magnetic therapy can effectively improve the clinical symptoms of patients with perimenopausal syndrome, reduce negative emotions such as depression and anxiety, and do not increase the occurrence of adverse reactions, with good safety. Therefore, it is worthy of clinical application and promotion.
|
|
|
|
|
|
[1] Jehan S, Jean-Louis G, Zizi F, et al. Sleep, Melatonin, and the menopausal transition: What are the links[J]. Sleep Sci, 2017, 10(1): 11.
[2] 杨金妮,汪莉莉,张旭烽,等.围绝经期妇女更年期综合征现状调查及影响因素分析[J].齐鲁护理杂志,2016,22(12):62~63.
[3] 戴云飞,肖泽萍,赵敏,等.ICD-11精神与行为障碍分类在中国的工作进展[J].中华精神科杂志,2015,48(2):126~127.
[4] Thompson E. Hamilton rating scale for anxiety (HAM-A)[J]. Occup Med, 2015, 65(7): 601~601.
[5] Kyle PR, Lemming OM, Timmerby N, et al. The validity of the different versions of the Hamilton Depression Scale in separating remission rates of placebo and antidepressants in clinical trials of major depression[J].Clin Psychopharmacol, 2016, 36(5): 453~456.
[6] 陈玉玲,张岩,曹玉凤,等.中医药治疗更年期综合征新进展[J].河北医学,2017,23(5):838~840.
[7] Toffol E, Kalleinen N, Haukka J, et al. Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life[J]. Menopause, 2014, 21(5): 493~500.
[8] Kornstein SG, McIntyre RS, Thase ME, et al. Desvenlafaxine for the treatment of major depressive disorder[J]. Expert Opin Pharmaco, 2014, 15(10): 1449~1463.
[9] Kirichenko TV, Myasoedova VA, Orekhova VA, et al. Phytoestrogen-rich natural preparation for treatment of climacteric syndrome and atherosclerosis prevention in perimenopausal women[J]. Phytother Res, 2017, 31(8): 1209~1214.
[10] Eisenhardt S, Fleckenstein J. Traditional Chinese medicine valuably augments therapeutic options in the treatment of climacteric syndrome[J]. Arch Gynecol Obstetr, 2016, 294(1): 193~200.
[11] Kim M, Kim AR, Park HJ, et al. Danggwijagyaksan for climacteric syndrome in peri-and postmenopausal women with a blood-deficiency dominant pattern: study protocol for a randomized, double-blind, placebo-controlled pilot trial[J]. Trials, 2018, 19(1): 41.
[12] 赵冰,赵瑞君,张桂敏,等.自拟更年疏肝健脾解郁汤配合针灸心理干预治疗肝气郁结型围绝经期抑郁症临床研究[J].河北医学,2016,22(7):1211~1213.
[13] 马元业,李刚,周东林,等.低频重复经颅磁刺激治疗首发抑郁症患者的临床疗效观察[J].国际精神病学杂志,2015,42(2):21~23. |
|
|
|
2018, Vol. 24 
